Versant Capital Management Inc decreased its holdings in shares of Cardiovascular Systems Inc (NASDAQ:CSII) by 73.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 988 shares of the medical device company’s stock after selling 2,775 shares during the quarter. Versant Capital Management Inc’s holdings in Cardiovascular Systems were worth $28,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in CSII. Quantamental Technologies LLC purchased a new position in shares of Cardiovascular Systems during the fourth quarter worth approximately $37,000. NJ State Employees Deferred Compensation Plan lifted its holdings in shares of Cardiovascular Systems by 11.1% during the fourth quarter. NJ State Employees Deferred Compensation Plan now owns 10,000 shares of the medical device company’s stock worth $285,000 after purchasing an additional 1,000 shares during the period. First Quadrant L P CA lifted its holdings in shares of Cardiovascular Systems by 47.9% during the fourth quarter. First Quadrant L P CA now owns 18,475 shares of the medical device company’s stock worth $526,000 after purchasing an additional 5,981 shares during the period. Diversified Trust Co lifted its holdings in shares of Cardiovascular Systems by 16.4% during the fourth quarter. Diversified Trust Co now owns 9,950 shares of the medical device company’s stock worth $283,000 after purchasing an additional 1,400 shares during the period. Finally, Vanguard Group Inc lifted its holdings in shares of Cardiovascular Systems by 1.0% during the third quarter. Vanguard Group Inc now owns 1,551,218 shares of the medical device company’s stock worth $60,714,000 after purchasing an additional 14,623 shares during the period. 79.66% of the stock is owned by institutional investors and hedge funds.
Cardiovascular Systems stock opened at $33.86 on Thursday. Cardiovascular Systems Inc has a one year low of $20.58 and a one year high of $40.00. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.38 and a quick ratio of 3.88. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of 677.20 and a beta of 2.09.
CSII has been the subject of several recent research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardiovascular Systems in a report on Wednesday, October 31st. BidaskClub raised Cardiovascular Systems from a “hold” rating to a “buy” rating in a report on Tuesday, January 22nd. Finally, Zacks Investment Research reaffirmed a “hold” rating on shares of Cardiovascular Systems in a report on Monday, November 12th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $47.50.
WARNING: This piece was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.baseballdailydigest.com/news/2019/02/14/versant-capital-management-inc-sells-2775-shares-of-cardiovascular-systems-inc-csii.html.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
See Also: Why is cost of goods sold important?
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.